METX — ME Therapeutics Holdings Share Price
Last trade - 00:00- CA$266.30m
- CA$264.40m
- 45
- 21
- 76
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 121.33 | ||
| Price to Tang. Book | 121.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -61.79% | ||
| Return on Equity | -101.22% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Aug | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ME Therapeutics Holdings Inc. is a preclinical stage biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. The Company’s focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. This antibody drug candidate is being developed to treat colorectal cancer. In addition to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. It has also initiated design and testing of two mRNA-based cancer therapeutic drug candidates. Its lead mRNA candidates target a known mechanism of immune stimulation.
Directors
- Last Annual
- August 31st, 2024
- Last Interim
- February 28th, 2025
- Incorporated
- March 9th, 2023
- Public Since
- October 12th, 2023
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 29,589,438
- Address
- 177 Robson Street, VANCOUVER, V6B 0N3
- Web
- https://www.metherapeutics.com/
- Phone
- Auditors
- Davidson & Company LLP
Upcoming Events for METX
Similar to METX
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
BetterLife Pharma
Canadian Securities Exchange
FAQ
As of Today at 22:01 UTC, shares in ME Therapeutics Holdings are trading at CA$9.00. This share price information is delayed by 15 minutes.
Shares in ME Therapeutics Holdings last closed at CA$9.00 and the price had moved by +151.4% over the past 365 days. In terms of relative price strength the ME Therapeutics Holdings share price has outperformed the Toronto Stock Exchange 300 Composite Index by +123.51% over the past year.
There is no consensus recommendation for this security.
Find out moreME Therapeutics Holdings does not currently pay a dividend.
ME Therapeutics Holdings does not currently pay a dividend.
ME Therapeutics Holdings does not currently pay a dividend.
To buy shares in ME Therapeutics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$9.00, shares in ME Therapeutics Holdings had a market capitalisation of CA$266.30m.
Here are the trading details for ME Therapeutics Holdings:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: METX
Based on an overall assessment of its quality, value and momentum ME Therapeutics Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ME Therapeutics Holdings. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +115.6%.
As of the last closing price of CA$9.00, shares in ME Therapeutics Holdings were trading +116.15% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ME Therapeutics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$9.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on ME Therapeutics Holdings' directors